What considerations govern the use of decongestants like pseudoephedrine in aircrew?

• A. They have no interaction with cabin environment
• B. They are banned for all aircrew
• C. They are recommended for all to prevent congestion during flight
• D. Potential tachycardia/hypertension and interactions; ensure clearance per policy

Answer: (D)

The safety question centers on the fact that pseudoephedrine and similar decongestants are sympathomimetic medicines that can boost alertness and relieve nasal congestion, but they also raise cardiovascular activity. By stimulating alpha-adrenergic receptors, these drugs constrict blood vessels and can push your heart rate and blood pressure upward. In the aircrew context, even modest increases in heart rate or blood pressure can degrade performance, especially during high-workload duties, hypoxic conditions, or stressors of flight. That means tachycardia, palpitations, restlessness, and insomnia are not just side effects—they’re potential safety risks that could affect judgment, coordination, and mission effectiveness.

Interactions are another key concern. Pseudoephedrine can interact with other medications or substances common in aviation or daily life, including monoamine oxidase inhibitors and certain antidepressants, which can produce dangerous elevations in blood pressure or other adverse effects. It can also amplify effects when mixed with caffeine or other stimulants, or interfere with drugs used to manage hypertension or cardiac conditions. Because these interactions vary between individuals, policy guidance often requires explicit clearance before use to ensure there are no contraindications or safety concerns for a given aircrew member.

Therefore, the appropriate approach is to evaluate the potential for tachycardia or hypertension and consider possible interactions, and to obtain clearance per aviation or medical policy before using such a medication. This safeguards both the crewmember’s health and flight safety.